drugset / Trial / NCT04033172
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
NaSingle-groupOpen-labelTreatment
Summary
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors. This study is a single-arm, prospective, single-center clinical study of pyrotinib plus fulvestrant as the therapy HR+/HER2+ metastatic breast cancer.
Timeline
- Start
- 2018-11-01
- Primary completion
- 2021-03-01
- Completion
- 2021-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 500 mg/m2 | Intramuscular |
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |